Congratulations

The data is a joke, the drug does not work and it's a toxic place to work. Best places to work my ass. Who did they buy to write that article???

 

They probably blackmailed somebody to write it.

I don't believe recruiters ever, but it says something when one that I have known for a while tells me she has more MNK resumes than ever. Mine is one of them.

When I first came on board, I was a believer. After so many years, I can't believe what we have become--pushing a horrifically priced pig hormone for anything and everything and trying to reverse engineer it to see if it actually does a damned thing.

 

Good bye

 

MBA Case Study in Price Gouging that leads to brand death

 

This will be a great case study in managements lack of willingness to take a long term strategy on Acthar, they will keep gouging the payers, alienate the MDs and slowly erode what has the potential to be a much wider used therapeutic option across disease states.

Now that the good money is gone, ARD will become a revolving door for the field and in-house.

 

continuing to gouge the payer will make our stay at malli very short.